
SwanBio Therapeutics
SwanBio Therapeutics developed gene therapies for neurological diseases, acquired and folded into Spur Therapeutics.
- Acquired
- Bala Cynwyd, PA, USUnited States
SwanBio Therapeutics was a clinical-stage biotechnology company focused on developing adeno-associated virus gene therapies for rare neurological diseases, including adrenomyeloneuropathy. The company advanced preclinical and clinical pipeline candidates designed to deliver disease-modifying therapies directly to the central nervous system.
In June 2024, Freeline Therapeutics completed the acquisition of SwanBio Therapeutics in a strategic consolidation backed by Syncona, creating the combined gene therapy company Spur Therapeutics. SwanBio pipeline programs, including its lead candidate SBT101, were integrated into Spur Therapeutics, with SwanBio operations and web presence absorbed into the new brand.
Similar Companies
Black Swan Pharmaceuticals

Prevail Therapeutics

Voyager Therapeutics

Lacerta Therapeutics

Code Biotherapeutics
codebiotx.com

Bluebird Bio
bluebirdbio.com

Excision BioTherapeutics

Affinia Therapeutics
affiniatx.com

Kriya Therapeutics
kriyatx.com

Escape Bio
escapebio.com

Chameleon Biosciences

Greenland Mines
anewmeds.com

StrideBio
stridebio.com

Jaguar Gene Therapy

Skylark Bio
skylarkbio.com

Theragene Pharmaceuticals

Apic Bio

Neurogene
neurogene.com

Spinogenix
spinogenix.com

Twister Biotech
twisterbiotech.com
Quick Facts
Who are SwanBio Therapeutics' competitors?
Companies similar to SwanBio Therapeutics include Black Swan Pharmaceuticals, Prevail Therapeutics, Voyager Therapeutics and Lacerta Therapeutics.
When was SwanBio Therapeutics founded?
SwanBio Therapeutics was founded in 2018.
Where is SwanBio Therapeutics' headquarters located?
SwanBio Therapeutics' headquarters is located in Bala Cynwyd, PA, US.
When was SwanBio Therapeutics' last funding round?
SwanBio Therapeutics' most recent funding round was for $10M (USD) in October 2023.
How much disclosed funding has SwanBio Therapeutics raised?
As of Oct 4, 2023, SwanBio Therapeutics has disclosed funding of $118M (USD). Undisclosed round amounts are excluded.
Classification
- Ownership
- Technology
- Geographic Exposure
- Revenue
- Customer
- Main Product
- Tags
- NAICS
- 540000Professional, Scientific, and Technical Services
- 541714Research and Development in Biotechnology (except Nanobiotechnology)
- 541000Professional, Scientific, and Technical Services
- 541700Scientific Research and Development Services
- 541710Research and Development in the Physical, Engineering, and Life Sciences
- SIC
- 8700Engineering, Accounting, Research, Management, And Related Services
- 8730Research, Development, And Testing Services
- 8731Commercial Physical and Biological Research
- Industry
- —Biotechnology Companies
- —Medical Organizations
Show 4 more industry codes
- NAICS
- 620000Health Care and Social Assistance
- SIC
- 8000Health Services
- 8040Offices And Clinics Of Other Health Practitioners
- 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified